Literature DB >> 36034996

Correlation between cholecystectomy and development of non-alcoholic liver disease in the mouse model.

Hye Young Kim1, Sung Ryol Lee2, Waqar Khalid Saeed3, Hyun Sung Kim4, Ju Hee Oh1, Dong Hee Koh5, Dae Won Jun1,6.   

Abstract

Background: Several clinical studies have suggested a strong correlation between cholecystectomy and the incidence of non-alcoholic fatty liver disease (NAFLD) although the exact correlation and causal relationship are unclear. This study aimed to investigate whether cholecystectomy increases the incidence of NAFLD or aggravates pre-existing NAFLD.
Methods: Standard diet-fed and high-fat (HF) diet-fed mice were subjected to sham operation and cholecystectomy. In study 1, 20 standard diet-fed C57BL/6N mice were sacrificed at months 1, 2, and 4 post-surgery. Meanwhile, in study 2, 25 HF diet-induced NAFLD C57BL/6N mice were biopsied at months 2 and 3 post-surgery and sacrificed at month 6 post-surgery. The hepatic fatty acid and bile acid metabolic pathways and the hepatic bile composition were evaluated.
Results: The bodyweight and biochemical parameters (hepatic enzyme, triglyceride, and cholesterol levels) were not significantly different between the standard diet-fed sham and cholecystectomy groups. The NAFLD activity score and the levels of hepatocyte apoptosis markers (Krt18 expression and DNA fragmentation) and de novo lipid synthesis genes were not significantly different between the standard diet-fed sham and cholecystectomy groups. Cholecystectomy did not exacerbate hepatic steatosis, inflammation, and ballooning in the HF diet-fed mice. Hepatic bile acid composition was not markedly different in the sham and cholecystectomy groups fed on standard or HF diet. Cholecystectomy significantly downregulated Cyp7a1 and Cyp27a1 mRNA levels at months 1 and 4 post-surgery but did not affect the degree of steatosis and triglyceride levels. Analysis of bile acid metabolism revealed that taurine-conjugated bile acids were significantly downregulated in the standard diet-fed and high-fat diet-fed mice, but the histological and biochemical parameters were not markedly different. Conclusions: Cholecystectomy did not increase the incidence of NAFLD in standard diet-fed mice. Additionally, NAFLD incidence was not significantly different between the HF diet-fed sham and cholecystectomy groups. Furthermore, the histological parameters were not markedly different between the sham and cholecystectomy groups fed on standard or HF diet. These findings suggest that cholecystectomy does not induce NAFLD. 2022 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Cholecystectomy; apoptosis; non-alcoholic fatty liver

Year:  2022        PMID: 36034996      PMCID: PMC9403915          DOI: 10.21037/atm-21-5414

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


Introduction

Cholecystectomy, which is a common surgical procedure worldwide, is a therapeutic strategy for cholecystitis and symptomatic gall stone disease. Although cholecystectomy is not reported to affect the total bile acid levels, it may modulate glucose and lipid homeostasis through different mechanisms (1,2). Glucose homeostasis is impaired in patients undergoing cholecystectomy due to increased postprandial glucose fluctuations and decreased postprandial duodenal bile acid concentration (3). Chen et al. suggested that some patients may not respond to cholecystectomy and exhibit a rapid release of bile acids into the intestine after meal intake. The lack of synchronization between the amount of bile acid and food results in metabolic stress and altered receptor activation [especially farnesoid X receptor (FXR)]. Activated FXR improves insulin sensitivity and downregulates the plasma glucose level by downregulating gluconeogenesis and upregulating glycogen synthesis (4). One study suggested that human gallbladder (GB) mucosa functions as an endocrine organ by secreting FGF19 into bile (5). The microbial diversity in patients with NAFLD is reported to be lower than that in healthy controls (6). Cholecystectomy impairs aging-related changes in gut microbial composition (7). Patients who have undergone cholecystectomy exhibit an increased abundance of bacterial species involved in bile acid metabolism (8). Bacterial dysbiosis-associated production of metabolites can be a feedback signal to the host (9). The contribution of the microbiome and other factors to the pathogenesis of NASH is unclear (10). The effect of cholecystectomy on bile composition and the metabolic network remains controversial. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease (11-13). Globally, rapid changes in lifestyle and diet have contributed to an increased prevalence of obesity and NAFLD. However, the ability of cholecystectomy to induce NAFLD is unknown. Various mechanisms have been suggested to be involved in the development of NAFLD although the exact mechanisms have not been elucidated. One potential mechanism underlying the development of NAFLD involves changes in bile acid composition or level (14-16). Several population-based studies in the United States have demonstrated that cholecystectomy is an independent risk factor for the occurrence of NAFLD (17). Similar results were obtained in a study comparing Asian patients subjected to cholecystectomy and those with GB stones as controls (18-20). However, a large population-based study conducted in China revealed the lack of correlation between cholecystectomy and NAFLD occurrence (21). Clinical studies have suggested a strong correlation between cholecystectomy and the incidence of NAFLD (17-20), although the exact correlation and causal relationship are unclear. This study aimed to investigate whether cholecystectomy increases the occurrence of NAFLD or aggravates pre-existing NAFLD. We present the following article in accordance with the ARRIVE reporting checklist (available at https://atm.amegroups.com/article/view/10.21037/atm-21-5414/rc).

Methods

Study design

Hepatic histological analysis was performed to investigate the effect of cholecystectomy on the healthy liver and pre-existing fatty liver. In particular, the effects of standard diet or 60% high-fat (HF) diet (Research Diets Inc., NJ, USA) on mouse hepatic histological parameters were evaluated at months 1, 2, and 4 post-surgery using liver biopsy.

Sequential liver biopsy

The changes in liver histological parameters were tracked at months 1, 2, and 4 post-surgery in the same mice without sacrificing them. Sequential liver biopsy was performed following a previously reported protocol (22). The first liver biopsy was performed in the left lateral lobe, while the second follow-up liver biopsy was performed in the left median lobe. Briefly, the mice were anesthetized by intraperitoneally injecting Zoletil and Rompun (1:1) before liver biopsy. The abdominal site was shaved and disinfected using a 10% iodine solution. Next, a midline incision was introduced, and a biopsy sample was collected from the left lateral lobe of the liver. A heated spatula was placed on the bleeding liver site to ensure hemostasis. The abdomen was sutured with a device. The same procedure was used for the second biopsy at the left median lobe.

Animal experiments (study 1): cholecystectomy in standard diet-fed mice

Twenty male C57BL6N mice (aged 8 weeks; Orient Animal Laboratory, Seoul, South Korea) were fed a standard diet (standard chow) and observed for 16 weeks. The mice were maintained under a 12/12 h light/dark cycle. All mice were divided into the following two groups: sham and cholecystectomy groups. To perform cholecystectomy, the mice were anesthetized by intraperitoneally injecting Zoletil and Rompun (1:1). After introducing a midline incision, the cystic duct was ligated and the GB was removed. The abdominal wall was closed in two layers after the surgery. Mice in the sham group underwent the same procedure without GB removal. At months 1, 2, and 4 post-surgery, the animals were euthanized, and serum and liver samples were obtained for further analysis.

Animal experiments (study 2): cholecystectomy in the HF diet-fed mice

Male C57BL/6N mice (Orient Animal Laboratory, Seoul, South Korea) aged 8 weeks were used to establish the fatty liver model. Mice were allowed to adapt for 1 week and fed on a 60% HF diet (Research Diets Inc, NJ, USA) for 4 weeks. The animals were then randomly divided into the sham (n=11) and cholecystectomy (n=14) groups. After cholecystectomy, the mice were maintained on HF diet. Liver biopsy was performed at months 2, 3, and 6 post-surgery. The total duration of the experiment was 24 weeks. Cholecystectomy was performed as described above. Mice in the sham group underwent the same surgical procedure without removal of the GB. The animals were followed up for 20 weeks after cholecystectomy. After 24 weeks, the mice were euthanized, and the serum and the liver tissue were harvested and frozen. The bodyweight of the mice was evaluated once every week. Liver weight and liver-to-body weight ratio were assessed. Experiments were performed under a project license (No. HY-IACUC-19-0022) granted by the Hanyang University Institutional Animal Care and Use Committee, in compliance with institutional guidelines for the care and use of animals.

Histological assessment of liver biopsy samples

Liver histological analysis was performed by a pathologist. The NASH clinical research network scoring system was used for histological grading (23). Steatosis, hepatocyte ballooning, and lobular inflammation were semi-quantitatively scored. The NAFLD activity score (NAS) was assessed by combining steatosis, hepatocyte ballooning, and lobular inflammation scores. Based on NAS, the cumulative scores of 0–2, 3–4, and, >5 were assigned as non-NASH, borderline NASH, and probable NASH, respectively (23). Hematoxylin and eosin (H&E) staining was performed to evaluate NAFLD. All histological images were re-evaluated by an independent pathologist who was blinded to the experimental group.

Histopathological analysis

Liver tissue fixed in formalin was trimmed and dehydrated to prepare a paraffin block. Paraffin-embedded tissues were sectioned to a thickness of 4 µm. The tissue samples were stained using the M30 cytoDEATH reagent (Sigma Aldrich, USA). Apoptosis was evaluated using a mouse monoclonal antibody that detects the caspase cleavage product of Krt18 in epithelial cells (M30). Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay was performed using the in situ cell death detection kit TMR red (Sigma Aldrich, USA) to detect single-stranded and double-stranded DNA breaks that occur during the early stages of apoptosis.

Serum analysis

For serum analysis, the euthanized animals were subjected to thoracotomy. The blood sample collected through cardiac puncture was centrifuged at 3,000 rpm and 4 ℃ for 15 min. The serum was stored at −80 ℃ until further analysis. The levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and bilirubin in the serum were measured using a biochemical analytical system (Hitachi-747; Hitachi, Tokyo, Japan).

Quantitative real-time polymerase chain reaction (qRT-PCR) analysis

Total RNA was extracted from the liver tissue using TRIzol reagent (Invitrogen, USA). The concentration of RNA was measured using a Nanodrop ND-2000 (Thermo Fisher Scientific Inc., USA). RNA purity was determined by measuring the A260/A280 ratio. The isolated RNA was reverse-transcribed into cDNA using SuperScript III (Invitrogen) and PrimeScript RT reagent kit (#RR037A; Takara, Japan). qRT-PCR analysis was performed in a 10-µL reaction mix using the LightCycler 480 system (Roche Diagnostics, Germany) with LightCycler480 SYBRGreen I Mastermix (Roche Diagnostics). The expression levels of target genes were normalized to those of Gapdh and expressed as fold changes. The primer sequences used in this study are shown in .
Table 1

Primers used in quantitative real-time polymerase chain reaction analysis

GenePrimer
Gapdh Forward: 5'-CAG CCT CAA GAT CAT CAG-3'
Reverse: 5'-TGT GGT CAT GAG TCC TTC-3'
Bax Forward: 5'-AGA TGA ACT GGA CAG CAA TAT GGA G-3'
Reverse: 5'-ACC CGG AAG AAG ACC TCT CG-3'
Bcl2 Forward: 5'-TGT GGA TGA CTG AGT ACC TGA ACC-3'
Reverse: 5'-TCA TTC AAC CAG ACA TGC ACC TAC-3'
Hnf4a Forward: 5'-TCT GCG AAC TCC TTC TGG AT-3'
Reverse: 5'-AGG AGC ACG TCC TTA AA-3'
Scd1 Forward: 5'-GCC CAC ATG CTC CAA GAG AT-3'
Reverse: 5'-GGC ACC GTC TTC ACC TTC TC-3'
Fas Forward: 5'-CCCTTTTTGAGGAGGCCAAT-3'
Reverse: 5'-GCTTCACGACTCCATCACGA-3'
Srebf1c Forward: 5'-GAAACACTCAGCAGCCACCA-3'
Reverse: 5'-CAAGCTTTGGACCTGGGTGT-3'
Bsep Forward: 5'-GGA CAA TGA TGT GCT TGT GG-3'
Reverse: 5'-CAC ACA AAG CCC CTA CCA GT-3'
Slc10a1 Forward: 5'-GGT GCC CTA CAA AGG CAT TA-3'
Reverse: 5'-ACA GCC ACA GAG AGG GAG AA-3'
Cd36 Forward: 5'-CCT TAA AGG AAT CCC CGT GT-3'
Reverse: 5'-TTG CCA ATG TCT AGC ACA CC-3'
Abcg5 Forward: 5'-GGT GTC CTG CAT GTG TCC TA-3'
Reverse: 5'-ATT TGC CTG TCC CAC TTC TG-3'
Cyp7a1 Forward: 5'-CCG TCT ACG CAT GTT TCT CA-3'
Reverse: 5'-GAA GGT TGC AGG AAT GGT GT-3'
Cyp27a1 Forward: 5'-GAG AGT GAA TCA GGG GAC CA-3'
Reverse: 5'-TCA GGA ATG GAG GGT TTC AG-3'
Star Forward: 5'-GGG CAT ACT CAA CAA CCA GGA-3'
Reverse: 5'-CGA AAC ACC TTG CCC ACA TC-3'
Cyp7b1 Forward: 5'-TTC TCT GGG CCT CTC TAG CA-3'
Reverse: 5'-CAG GGC TTC CAT AGC TTC AG-3'
Cyp46a1 Forward: 5'-CAT GAG ACT TCT GCC AAC CA-3'
Reverse: 5'-CTT GGA ACC GAC AAC CTC AT-3'
Cyp39a1 Forward: 5'-TCA TTC TGG AAC CCT CTT GC-3'
Reverse: 5'-CAG CCC AAA GTA CGA CCA GT-3'
Cyp8b1 Forward: 5'-AGT TGC AGC GTC TCT TCC AT-3'
Reverse: 5'-CCT TGC TCC CTC AGA AAC TG-3'

Metabolomic assay

Liver tissue was homogenized in an extraction solvent. The homogenate was centrifuged at 14,000 rpm for 10 min. The supernatant was subjected to liquid chromatography-tandem mass spectrometry (LC/MS) analysis using a UPLC-Q-TOF MS instrument (Vion, Waters, Milford, MA, USA) equipped with an Acquity UPLC BEH C18 column. The LC conditions were as follows: solvent A, 0.1% formic acid (FA) in water; solvent B, 0.1% FA in acetonitrile (ACN); flow rate, 0.35 mL/min; injection volume, 1 µL. The MS conditions were as follows: mode, multiple reaction monitoring; capillary voltage, 3 kV; sample cone voltage, 40 V; desolvation gas flow rate, 800 L/h; cone gas flow rate, 30 L/h; desolvation temperature, 400 ℃; ion source temperature, 100 ℃; lock mass, leucine-enkephalin (556.2771 Da). Data were processed using UNIFI version 1.8.2.169 (Waters). Partial least squares-discriminant analysis (PLS-DA) and permutation test were performed, and variable importance for projection and P values were determined using SIMCA-P+ version 12.0.1, Umetrics, Sweden.

Statistical analysis

All data are expressed as mean ± standard error of mean. Statistical analysis was performed using PRISM 8.02. The experiments were performed in triplicate. The data for the standard diet-fed sham and cholecystectomy groups were compared using one-way analysis of variance, whereas the results of liver weight, liver/bodyweight ratio, serum biochemical, and qRT-PCR analyses for HF diet-fed mice study 2 were compared using the unpaired t-test. Differences were considered significant at P<0.05.

Results

Effect of cholecystectomy on the histological and clinical parameters in standard diet-fed mice

The liver tissues of mice fed on a standard diet were biopsied at months 1, 2, and 4 post-surgery. The tissue sections were subjected to H&E staining to compare the NAS between the sham and cholecystectomy groups (). The degree of steatosis and lobular inflammation were not significantly different between the sham and cholecystectomy groups at months 1, 2, and 4 post-surgery (). However, the ballooning degeneration score and NAS in the cholecystectomy group were significantly higher than those in the sham group at months 1 (P=0.007), 2 (P=0.018), and 4 (P=0.002) post-surgery. The AST, ALT, triglyceride (TG), and cholesterol levels were not significantly different between the sham and cholecystectomy groups (). Additionally, the histological scores of the H&E-stained sections were not significantly different between the sham and cholecystectomy groups at months 1, 2, and 4 post-surgery ().
Figure 1

Effects of cholecystectomy on the liver histological parameters in standard diet-fed mice. (A) Experimental schedule of sham operation and cholecystectomy in standard diet-fed mice. (B) Histopathological analysis of liver steatosis, lobular inflammation, ballooning degeneration, and NAS. (C) Serum levels of ALT, AST, triglycerides, and cholesterol. (D) Representative images of hematoxylin and eosin-stained liver sections (magnification: 200×). (E) Representative immunohistochemical images of apoptotic cells in the liver sections probed with M30 antibodies (magnification: 200×). (F) Apoptosis was determined using TUNEL staining (green; magnification: 200×). (G) M30-positive area was quantified using the image analysis system. mRNA levels of Bax and Bcl2 were determined using quantitative real-time polymerase chain reaction analysis. All data were given as the mean ± SEM with *, P<0.05 from the one-way ANOVA test with Sidak’s multiple comparisons test by GraphPad Prism8 (*, P=0.01–0.05; ***, P=0.001). NAS, non-alcoholic fatty liver disease activity score; XGB, cholecystectomy; TG, triglyceride; H&E, hematoxylin & eosin; IHC, immunohistochemistry; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling; SEM, standard error of mean; ANOVA, analysis of variance.

Effects of cholecystectomy on the liver histological parameters in standard diet-fed mice. (A) Experimental schedule of sham operation and cholecystectomy in standard diet-fed mice. (B) Histopathological analysis of liver steatosis, lobular inflammation, ballooning degeneration, and NAS. (C) Serum levels of ALT, AST, triglycerides, and cholesterol. (D) Representative images of hematoxylin and eosin-stained liver sections (magnification: 200×). (E) Representative immunohistochemical images of apoptotic cells in the liver sections probed with M30 antibodies (magnification: 200×). (F) Apoptosis was determined using TUNEL staining (green; magnification: 200×). (G) M30-positive area was quantified using the image analysis system. mRNA levels of Bax and Bcl2 were determined using quantitative real-time polymerase chain reaction analysis. All data were given as the mean ± SEM with *, P<0.05 from the one-way ANOVA test with Sidak’s multiple comparisons test by GraphPad Prism8 (*, P=0.01–0.05; ***, P=0.001). NAS, non-alcoholic fatty liver disease activity score; XGB, cholecystectomy; TG, triglyceride; H&E, hematoxylin & eosin; IHC, immunohistochemistry; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TUNEL, terminal deoxynucleotidyl transferase dUTP nick-end labeling; SEM, standard error of mean; ANOVA, analysis of variance.

Effect of cholecystectomy on apoptosis-related markers in standard diet-fed mice

Hepatic Krt18 expression and TUNEL staining intensity (indicates the degree of DNA fragmentation) were not significantly different between the sham and cholecystectomy groups. However, hepatic Krt18 expression and the TUNEL staining intensity at month 1 post-surgery were markedly different from those at months 2 and 4 post-surgery. This indicated that apoptosis at month 1 post-surgery was mitigated at months 2 and 4 post-surgery (, left graph). The expression of Bax, a pro-apoptotic gene, was significantly downregulated in the cholecystectomy group at months 1 (P<0.001), 2 (P<0.001), and 4 (P=0.012) post-surgery. In contrast, the expression of Bcl2, an anti-apoptotic marker, was not significantly between the sham and cholecystectomy groups (, middle and right panel). Primer sequences are provided in .

Effect of cholecystectomy on hepatic fat and bile acid synthesis pathways in standard diet-fed mice

The changes in the cholesterol and bile acid synthesis pathways were compared between the standard diet-fed sham and cholecystectomy groups. The expression levels of fatty acid biosynthesis-related (Srebf1c, Fas, Scd1, and Hnf4a) genes were not significantly different between the two groups. Compared with those in the sham group, the expression levels of Abcg5 (involved in bile secretion) and Cd36 (involved in the secretion of other fatty acids) were downregulated in the cholecystectomy group (). The expression levels of classical bile acid synthesis pathway-related genes in the cholecystectomy group were lower than those in the sham group. At months 1 and 4 post-surgery, the hepatic expression levels of Cyp7a1, which encodes a rate-limiting enzyme in the acidic pathway, in the cholecystectomy group were downregulated when compared with those in the sham group (). Additionally, the expression levels of Cyp7b1, which encodes a rate-limiting enzyme in the acidic pathway, in the cholecystectomy group were significantly lower than those in the sham group at months 1, 2, and 4 post-surgery (). These gene primer sequences are provided in .
Figure 2

Effect of cholecystectomy on the hepatic physiological pathways in standard diet-fed mice. mRNA levels of (A) StarD1, Abcg5, and Hnf4a, (B) Scd1, Fas, and Srebf1c, (C) Bsep, Ntcp, and Cd36, and (D) Cyp7a1, Cyp27a1, Cyp8b1, Cyp7b1, Cyp46a1, and Cyp39a1 were determined using quantitative real-time polymerase chain reaction analysis. All data are presented as mean ± standard error of mean (one-way analysis of variance, followed by Šídák multiple comparisons test using GraphPad Prism8 (*, P=0.01–0.05; **, P=0.001–0.01; ***, P=0.001; ****, P<0.0001). (E) The PLS-DA score scatter plot (left panel) and the permutation test of the PLS-DA (right panel) results. (F) T-UDCA, T-CDCA, and T-DCA were selectively represented from the metabolome profile data of PLS-DA and permutation test (**, P=0.001–0.01; ***, P=0.001; ****, P<0.0001). (G) Total bile acids were represented from the metabolome profile data of PLS-DA of mice used in study 1 (****, P<0.0001). XGB, cholecystectomy; T-UDCA, taurine-conjugated ursodeoxycholic acid; T-CDCA, taurine-conjugated chenodeoxycholic acid; T-DCA, taurine-conjugated deoxycholic acid; CA-S, cholic acid; T-CA-S, tauro-cholic acid-sulfate; T-LCA, tauro-lithocholic acid; CA, cholic acid; LCA-S, lithocholic acid sulfate; T-MCA, tauro-muricholic acid; PLS-DA, partial least-squares discriminant analysis.

Effect of cholecystectomy on the hepatic physiological pathways in standard diet-fed mice. mRNA levels of (A) StarD1, Abcg5, and Hnf4a, (B) Scd1, Fas, and Srebf1c, (C) Bsep, Ntcp, and Cd36, and (D) Cyp7a1, Cyp27a1, Cyp8b1, Cyp7b1, Cyp46a1, and Cyp39a1 were determined using quantitative real-time polymerase chain reaction analysis. All data are presented as mean ± standard error of mean (one-way analysis of variance, followed by Šídák multiple comparisons test using GraphPad Prism8 (*, P=0.01–0.05; **, P=0.001–0.01; ***, P=0.001; ****, P<0.0001). (E) The PLS-DA score scatter plot (left panel) and the permutation test of the PLS-DA (right panel) results. (F) T-UDCA, T-CDCA, and T-DCA were selectively represented from the metabolome profile data of PLS-DA and permutation test (**, P=0.001–0.01; ***, P=0.001; ****, P<0.0001). (G) Total bile acids were represented from the metabolome profile data of PLS-DA of mice used in study 1 (****, P<0.0001). XGB, cholecystectomy; T-UDCA, taurine-conjugated ursodeoxycholic acid; T-CDCA, taurine-conjugated chenodeoxycholic acid; T-DCA, taurine-conjugated deoxycholic acid; CA-S, cholic acid; T-CA-S, tauro-cholic acid-sulfate; T-LCA, tauro-lithocholic acid; CA, cholic acid; LCA-S, lithocholic acid sulfate; T-MCA, tauro-muricholic acid; PLS-DA, partial least-squares discriminant analysis.

Effect of cholecystectomy on hepatic bile acid composition in standard diet-fed mice

Next, this study examined whether the changes in gene expression related to bile production affect the bile acid composition in the liver. Metabolomics analysis was performed to confirm the changes in the composition of bile acids in the liver after GB resection. PLS-DA indicated that the distribution of bile acid composition was not significantly different between the sham and cholecystectomy groups (). The taurine-conjugated ursodeoxycholic acid (T-UDCA), taurine-conjugated chenodeoxycholic acid (T-CDCA), and taurine-conjugated deoxycholic acid (T-DCA) levels in the cholecystectomy group were significantly lower than those in the sham group (P<0.001) ().

Effect of cholecystectomy on the histological and clinical parameters in HF diet-fed mice

Mice fed on HF diet for 1 month to induce fatty liver were subjected to cholecystectomy. Sequential liver biopsy was performed without sacrificing the mice at months 2, 4, and 6 post-surgery (). The liver weight, bodyweight, and liver/body weight ratio were not significantly different between the sham and cholecystectomy groups (). The NAS in the cholecystectomy group was significantly higher than that in the sham operation group at month 2 post-surgery (P=0.008). However, the NAS was not significantly different between the sham and cholecystectomy groups at months 3 and 6 post-surgery (). Additionally, the serum AST, ALT, and TG levels were not significantly different between the cholecystectomy and sham groups at the end of the study period (6 months) ().
Figure 3

Effect of cholecystectomy on liver histological parameters in HF diet-fed mice. (A) The experimental schedule of sham operation and cholecystectomy in HF diet-fed mice (Study 2). (B,C) BW, LW, and LW/BW ratio in the sham and cholecystectomy groups fed on HF diet. (D) Histopathological analysis of liver steatosis, lobular inflammation, ballooning degeneration, and NAS. (E) Serum levels of ALT, AST, triglycerides, and cholesterol. (F) Representative images of hematoxylin and eosin-stained liver sections (magnification: 200×). (G) Representative immunohistochemical images of apoptotic cells in the liver sections probed with M30 antibodies (magnification: 200×). Scale bar =100 µm. (H) M30-positive area was quantified using the image analysis system. mRNA levels of Bax and Bcl2 were determined using quantitative real-time polymerase chain reaction analysis. All data were given as the mean ± SEM with P<0.05 from the one-way ANOVA test with Sidak’s multiple comparisons test by GraphPad Prism8 (**, P=0.001–0.01). XGB, cholecystectomy; H&E, hematoxylin & eosin; IHC, immunohistochemistry; HF, high-fat; BW, bodyweight; LW, liver weight; NAS, non-alcoholic fatty liver disease activity score; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SEM, standard error of mean; ANOVA, analysis of variance.

Effect of cholecystectomy on liver histological parameters in HF diet-fed mice. (A) The experimental schedule of sham operation and cholecystectomy in HF diet-fed mice (Study 2). (B,C) BW, LW, and LW/BW ratio in the sham and cholecystectomy groups fed on HF diet. (D) Histopathological analysis of liver steatosis, lobular inflammation, ballooning degeneration, and NAS. (E) Serum levels of ALT, AST, triglycerides, and cholesterol. (F) Representative images of hematoxylin and eosin-stained liver sections (magnification: 200×). (G) Representative immunohistochemical images of apoptotic cells in the liver sections probed with M30 antibodies (magnification: 200×). Scale bar =100 µm. (H) M30-positive area was quantified using the image analysis system. mRNA levels of Bax and Bcl2 were determined using quantitative real-time polymerase chain reaction analysis. All data were given as the mean ± SEM with P<0.05 from the one-way ANOVA test with Sidak’s multiple comparisons test by GraphPad Prism8 (**, P=0.001–0.01). XGB, cholecystectomy; H&E, hematoxylin & eosin; IHC, immunohistochemistry; HF, high-fat; BW, bodyweight; LW, liver weight; NAS, non-alcoholic fatty liver disease activity score; ALT, alanine aminotransferase; AST, aspartate aminotransferase; SEM, standard error of mean; ANOVA, analysis of variance.

Effect of cholecystectomy on hepatic bile acid composition in HF diet-fed mice

The hepatic histological parameters were not significantly different between the sham and cholecystectomy groups at months 2, 3, and 6 post-surgery (). The results of the TUNEL assay revealed that apoptosis was not significantly different between the sham and cholecystectomy groups. mRNA levels of Bax and Bcl2 (apoptosis markers) were not significantly different between the sham and cholecystectomy groups (). Stard1 (cholesterol transport marker), Abcg5 (involved in bile secretion marker) and Hnf4α (lipid homeostasis marker) genes were not significantly different between the sham and cholecystectomy groups (). Comparative analysis of the expression of liver fat synthesis and bile acid production-related genes () revealed that Cyp7b1 expression was upregulated in the cholecystectomy group, whereas the expression of other genes was not significantly different between the two groups (). Hepatic bile acid composition in the sham and cholecystectomy groups was evaluated at month 6 post-surgery. PLS-DA revealed that bile acid composition was not significantly different between the sham and cholecystectomy groups (). However, T-UDCA and T-CDCA levels were significantly downregulated in the cholecystectomy group (P<0.001) ().
Figure 4

Effect of cholecystectomy on the hepatic metabolite levels and bile acid composition in high-fat diet-fed mice. mRNA levels of (A) StarD1, Abcg5, and Hnf4a, and (B) Scd1, Fas, and Srebf1c, (C) Bsep, Slc10a1, and Cd36, (D) Cyp7a1, Cyp27a1, Cyp39a1, Cyp7b1, Cyp8b1, and Cyp46a1 were determined using quantitative real-time polymerase chain reaction analysis. All data are presented as mean ± standard error of mean (one-way analysis of variance, followed by Šídák multiple comparisons test using GraphPad Prism8 (*, P=0.01–0.05; **, P=0.001–0.01; ***, P=0.001; ****, P<0.0001). (E) The PLS-DA score scatter plot (left panel) and the permutation test of the PLS-DA (right panel) results. (F) T-UDCA, T-CDCA, and T-DCA were selectively represented from the metabolome profile data of PLS-DA and permutation test (****, P<0.0001). (G) Total bile acids were selectively represented from the metabolome profile data of PLS-DA of mice used in study 2 (*, P=0.01–0.05; ****, P<0.0001). XGB, cholecystectomy; T-UDCA, taurine-conjugated ursodeoxycholic acid; T-CDCA, taurine-conjugated chenodeoxycholic acid; T-DCA, taurine-conjugated deoxycholic acid; CA-S, cholic acid; T-CA-S, tauro-cholic acid-sulfur; T-LCA, tauro-lithocholic acid; CA, cholic acid; LCA-S, lithocholic acid sulfate; T-MCA, tauro-muricholic acid; PLS-DA, partial least-squares discriminant analysis.

Effect of cholecystectomy on the hepatic metabolite levels and bile acid composition in high-fat diet-fed mice. mRNA levels of (A) StarD1, Abcg5, and Hnf4a, and (B) Scd1, Fas, and Srebf1c, (C) Bsep, Slc10a1, and Cd36, (D) Cyp7a1, Cyp27a1, Cyp39a1, Cyp7b1, Cyp8b1, and Cyp46a1 were determined using quantitative real-time polymerase chain reaction analysis. All data are presented as mean ± standard error of mean (one-way analysis of variance, followed by Šídák multiple comparisons test using GraphPad Prism8 (*, P=0.01–0.05; **, P=0.001–0.01; ***, P=0.001; ****, P<0.0001). (E) The PLS-DA score scatter plot (left panel) and the permutation test of the PLS-DA (right panel) results. (F) T-UDCA, T-CDCA, and T-DCA were selectively represented from the metabolome profile data of PLS-DA and permutation test (****, P<0.0001). (G) Total bile acids were selectively represented from the metabolome profile data of PLS-DA of mice used in study 2 (*, P=0.01–0.05; ****, P<0.0001). XGB, cholecystectomy; T-UDCA, taurine-conjugated ursodeoxycholic acid; T-CDCA, taurine-conjugated chenodeoxycholic acid; T-DCA, taurine-conjugated deoxycholic acid; CA-S, cholic acid; T-CA-S, tauro-cholic acid-sulfur; T-LCA, tauro-lithocholic acid; CA, cholic acid; LCA-S, lithocholic acid sulfate; T-MCA, tauro-muricholic acid; PLS-DA, partial least-squares discriminant analysis.

Discussion

This study investigated whether cholecystectomy could increase the incidence of fatty liver in mice. Cholecystectomy did not induce fatty liver in standard diet-fed mice. Furthermore, cholecystectomy did not increase the risk of fatty liver or exacerbate fatty liver in HF diet-fed mice. The major strength of this study is the continuous monitoring of the development of fatty liver through liver biopsy without sacrificing mice after cholecystectomy. A recent study showed that NAFLD could be induced by altering the intestinal microbiome profile after cholecystectomy in the standard diet-fed and HF diet-fed groups (24). However, one study involving 32,428 human subjects reported that cholecystectomy may not be a risk factor for fatty liver disease (21). Additionally, the increased prevalence of NAFLD among patients undergoing cholecystectomy was attributed to the common risk factors. Thus, cholecystectomy has no causal relationship with the development and progression of NAFLD (25). Previous reports have shown increased levels of bile acid in the early stages after cholecystectomy. However, the bile acid levels reach a steady-state at month 3 post-surgery. No marked changes in the amount and conversion rate of bile acids were observed among non-surgical patients (26). Therefore, the inconsistency of results between this study and previous studies can be attributed to different post-cholecystectomy analysis periods. Cholecystectomy is an effective and safe treatment for GB diseases (1). Recent epidemiological studies have reported that NAFLD, dyslipidemia, and hyperglycemia are related to the occurrence of metabolic syndromes after GB resection (2,16,17,19,27,28). However, the causal relationship between cholecystectomy and metabolic disease and the underlying mechanism are unclear. Cholecystectomy does not change the bile acid pool size or composition but can increase enterohepatic circulation. Several studies have suggested that increasing bile acid exposure affects the metabolic parameters (1,17,29-31). Amigo et al. demonstrated that cholecystectomy did not affect the bile acid pool size but doubled the bile acid circulation rate (32). The authors reported that cholecystectomy increased the hepatic triglyceride content and very-low-density lipoprotein production in mice. However, the authors did not demonstrate histological changes in the liver or examine the development of fatty liver. In this study, serum triglyceride concentration transiently increased at month 1 post-cholecystectomy. However, the serum triglyceride concentrations were similar between the two groups at month 2 post-cholecystectomy. These results suggest that cholecystectomy promotes changes in the metabolic pathways but does not induce histological changes in the liver. Several limitations were associated with this animal study. The GB resection condition in mice is different from that in humans. In humans, cholecystectomy is performed to alleviate gallstones or chronic inflammation. Thus, the pre-existing altered metabolism in humans cannot be directly compared to cholecystectomy-induced altered metabolism in mice. In study 1, the number of mice in the sham group was only 2 at month 4 post-surgery, which may affect the statistical power. However, this is a proof of study for hypothesis testing analyzing the possibility of serialization. Therefore, additional experiments are needed with a large number of animals. Furthermore, the bile acid composition of mice is significantly different from that of humans. The final product of bile acid metabolism in humans is CDCA. In contrast, CDCA is metabolized to MCA in mice. The human intestinal microbiota transforms primary bile acids (CA and CDCA) into secondary bile acids (DCA and LCA). In mice, hepatic 7α-hydroxylase transforms secondary bile acid into primary bile acid (33). Several studies have shown that cholecystectomy regulates metabolic indicator levels by activating FXR (34). Bile acid-activated FXR increases insulin sensitivity, downregulates gluconeogenesis, and upregulates glycogen synthesis, which leads to decreased plasma glucose levels (4,35). Furthermore, FXR decreases plasma TG and cholesterol levels. However, activation of the FXR pathway by increasing the bile acid circulation rate without affecting the bile acid pool size is unknown. FXR is a master transcription factor that regulates hepatic bile acid synthesis and metabolism. Hence, this study examined the changes in the bile acid synthesis pathway. Cholecystectomy did not affect the hepatic bile acid composition but downregulated the levels of taurine-conjugated bile acids. Analysis of bile composition in the liver revealed that taurine-conjugated bile acid levels decreased in the standard diet-fed and HF diet-fed cholecystectomy groups. Previous studies have demonstrated that taurine exerts antioxidant and anti-inflammatory effects (36). Administration of taurine decreases cholesterol levels in the serum and liver and increases the fecal excretion of bile acid and taurine-conjugated bile acids (37). In this study, taurine-conjugated bile acid levels in the cholecystectomy group were lower than those in the sham operation group. Reduction of taurine-conjugated bile acids may be associated with anti-oxidative and anti-apoptotic effects. Further studies are needed to elucidate the underlying mechanisms. CYP7A1 is a rate-limiting enzyme in the classic bile acid synthesis pathway (38). One study showed that cholecystectomy significantly upregulated the expression of Cyp7a1 in female mice without affecting the bodyweight (39). Nuclear receptors such as PXR, PPARα, and LXRα regulate Cyp7a1 expression (33). In this study, the expression levels of Cyp7a1 and Cyp27a1 were significantly downregulated at months 1 and 4 post-surgery. The underlying mechanism must be elucidated in the future. In conclusion, this study demonstrated that the incidence of NAFLD did not increase after cholecystectomy in mice with healthy and fatty livers. Similarly, cholecystectomy did not significantly affect hepatic bile acid composition and bile acid synthesis pathways. The article’s supplementary files as
  39 in total

1.  Cholecystectomy increases hepatic triglyceride content and very-low-density lipoproteins production in mice.

Authors:  Ludwig Amigo; Constanze Husche; Silvana Zanlungo; Dieter Lütjohann; Marco Arrese; Juan Francisco Miquel; Attilio Rigotti; Flavio Nervi
Journal:  Liver Int       Date:  2010-10-29       Impact factor: 5.828

2.  Cholecystectomy does not significantly increase the risk of fatty liver disease.

Authors:  Hong-Gang Wang; Li-Zhen Wang; Hang-Jiang Fu; Peng Shen; Xiao-Dan Huang; Fa-Ming Zhang; Rui Xie; Xiao-Zhong Yang; Guo-Zhong Ji
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 3.  The Influence of the Microbiome on NAFLD and NASH.

Authors:  Somaya A M Albhaisi; Jasmohan S Bajaj
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

Review 4.  Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism.

Authors:  Annika Wahlström; Sama I Sayin; Hanns-Ulrich Marschall; Fredrik Bäckhed
Journal:  Cell Metab       Date:  2016-06-16       Impact factor: 27.287

5.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  Effects of cholecystectomy on the kinetics of primary and secondary bile acids.

Authors:  F Berr; F Stellaard; E Pratschke; G Paumgartner
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

7.  Long-term effects of cholecystectomy on bile acid metabolism.

Authors:  G A Kullak-Ublick; G Paumgartner; F Berr
Journal:  Hepatology       Date:  1995-01       Impact factor: 17.425

Review 8.  Bariatric surgery for non-alcoholic steatohepatitis in obese patients.

Authors:  Norberto C Chavez-Tapia; Felix I Tellez-Avila; Tonatiuh Barrientos-Gutierrez; Nahum Mendez-Sanchez; Javier Lizardi-Cervera; Misael Uribe
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 9.  Bile acids as regulatory molecules.

Authors:  Phillip B Hylemon; Huiping Zhou; William M Pandak; Shunlin Ren; Gregorio Gil; Paul Dent
Journal:  J Lipid Res       Date:  2009-04-03       Impact factor: 5.922

10.  Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis.

Authors:  John Y L Chiang; Jessica M Ferrell
Journal:  Liver Res       Date:  2020-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.